HuLuc 63

Share this animation:

PDL BioPharma asked XVIVO to show how a novel humanized antibody, HuLuc 63, appears to induce anti-tumor effects by binding to a protein expressed only on the surface of myeloma cells. This initiates antibody-dependent cytotoxic activity which targets myeloma cells while leaving healthy cells intact.

Share It:
Contact XVIVO


PDL BioPharma

XVIVO is in a unique class of crackerjack design companies with honest, capable, supremely talented artists, graphic designers, strategists, and project managers, all of whom are committed to excellence in animation. They understand the unique power of this still evolving art form, its ability to distill otherwise unapproachable biochemical data, and to make it available to the untrained marketing professional, all the while preserving the integrity of the science for the experts who have committed their life’s work to drug discovery and development. Ain’t it easy when you know how to do it?

John Lapolla, Asante Communications, LLC
Share this animation: